KENS 5: Stressing the importance of the HPV vaccine

January 31, 2020

Dr. Erin Mankus who is an assistant professor of obstetrics and gynecology at UT Health San Antonio, and works as an obstetrician and gynecologist explains why the HPV vaccine is key to prevent infection and cervical cancer.

San Francisco Chronicle: Living liver donors generously swap, saving 2 recipients

January 30, 2020

Transplant physicians with the Long School of Medicine at The University of Texas Health Science Center at San Antonio performed transplants on two patients whose livers were failing. The transplants were notable because, for what transplant program coordinators believe is the first time in the U.S., each donor provided a section of her liver to a recipient she previously did not know but with whom she was a compatible match.

School of Nursing provides Narcan to UNT institutions to support lifesaving training

January 30, 2020

Dr. Lisa Cleveland, of the School of Nursing, and her team went to the UNT Health Science Center on Jan. 28 to provide 9,000 doses of Narcan nasal spray. Students there led a training on how to administer the medication.

Fox 29/News 4: Clinical trials to benefit patients

January 30, 2020

Dr. Chethan Ramamurthy, assistant professor of genitourinary (GU) medical oncology for Mays Cancer Center, educates the public on what clinical trials are, the impact and benefits of having patients enroll, and how the Mays Cancer Center is at the forefront of groundbreaking research in our community and beyond.

OncLive: Dr. Ruben Mesa on JAK inhibitors in the pipeline for myelofibrosis

January 29, 2020

Ruben A. Mesa, M.D., director of Mays Cancer Center at the newly named UT Health San Antonio MD Anderson Cancer Center, discusses the approval of fedratinib (Inrebic) in myelofibrosis and other JAK inhibitors in the treatment pipeline. Read the full story at OncLive

Targeted Oncology: Highlighting current advances for the treatment of myeloproliferative neoplasms

January 28, 2020

Ruben Mesa discusses the current state of the treatment landscape for patients with myeloproliferative neoplasms (MPNs).